Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YOLT-202 in Alpha-1 Antitrypsin Deficiency
NCT07193615Phase 1Active, not recruiting
- Sponsor
- Renji Hospital
- Start
- Jun 2025
- Primary completion
- Jan 2027
- Modality
- Gene Silencing, CRISPR-Cas9, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SERP-01 in alpha-1 antitrypsin deficiency (AATD), sponsored by Renji Hospital. Primary endpoint: Safety of YOLT-202 at 52 weeks. Started Jun 2025; status: active, not recruiting.
02
Drugs
SERP-01
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT07193615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07193615.